Application of an iPSC‐Derived Organoid Model for Localized Scleroderma Therapy (Adv. Sci. 16/2022). Issue 16 (3rd June 2022) - Ma, Jie
Abstract : Localized Scleroderma Therapy Human‐induced pluripotent stem cell (hiPSC)‐derived epithelial and mesenchymal (EM) organoids can be used to investigate the therapeutic potential for the recovery of localized scleroderma (LoS) associated phenotypes and skin‐associated functions. In article number 2106075, Wu Zhong, Shuyang Zhang, Ling Leng, and co‐workers, establish an experimental EM organoid model from hiPSC to significantly reduce the degree of skin fibrosis and inflammation. Most importantly, it promotes the regeneration of epidermis and their appendages, providing a new therapeutic alternative for patients suffering from disfigurement and skin function defects caused by LoS.